Characterizing liver cancer and chronic liver disease through sample collection
Official title: Deep Liver Phenotyping and Immunology Study
Run by University of Oxford · NCT04946773 · Data updated 2026-11-12
This study is trying to find early signs of liver cancer by collecting and comparing blood, urine, and liver samples from people with liver cancer and those with chronic liver disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University of Oxford Academic / other |
| Locations | 1 site (Oxford, Oxfordshire) |
| Status | Recruiting |
| Started | March 12, 2021 |
| Main results expected | October 31, 2040 |
| Study ends | October 31, 2040 |
| Registry record updated | April 6, 2022 |
| Trial ID | NCT04946773 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals aged 18 to 75 with either diagnosed liver malignancies or chronic liver disease.
✕Probably not a fit
Patients who are pregnant or unable to provide informed consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify early biomarkers for hepatocellular carcinoma and cholangiocarcinoma by collecting blood, urine, and liver samples from patients. It will compare samples from individuals with liver cancer to those with chronic liver disease to understand the cancer-predisposing 'field effect'. The study will utilize techniques such as fine needle aspiration for minimally invasive sample collection and will analyze these samples through flow cytometry, molecular biology, and transcriptomic analysis. The ultimate goal is to develop a multi-parametric model for early cancer detection.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection of liver cancers, allowing for more effective treatment options.
How similar studies have gone: Other studies have shown promise in identifying biomarkers for liver cancers, but this approach may offer novel insights into the predisposing factors.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study. * Male or Female, aged 18 years to 75 years. Malignancy Cohort: extra inclusion criteria - Diagnosed with a malignancy or with clinical suspicion of a malignancy affecting the Liver or Biliary Tree. Control cohort: extra inclusion criteria \- Patients with confirmed chronic non-malignant hepatobiliary disease. Additional Inclusion Criteria for Patients Undergoing optional Liver FNA * Willing to undergo ultrasound guided liver FNA (unless specific contra-indications to the procedure apply). * Has undergone appropriate clinical imaging of the upper abdomen (US/CT/MRI) within the last 12 months. * Full blood count (FBC) and coagulation profile (Coag) checked within 30 days prior to FNA procedure (Baseline Visit). Exclusion Criteria: * Unable to consent. * Pregnancy. * Any concern by the investigator regarding the safe participation of the patient in the study; or investigator's consideration, for any other reason, that a patient is inappropriate for participation in the study. Additional Exclusion Criteria for Patients Undergoing optional Liver FNA (These criteria will exclude a patient from having FNA as part of the study) * Significant comorbid medical condition(s) which may in the opinion of the investigator increase the risk of an FNA Liver. * Coagulopathy - International Normalized Ratio (INR) \>1.3, Prothrombin Time (PT) \>16 seconds, Platelet count \<100 x 10\^3/L. * Known bleeding disorder (e.g. Haemophilia). * Current use of an oral/injectable anticoagulant medication. * Current use of an oral antiplatelet agent. * The presence of ascites.
Where it's running
-
John Radcliffe Hospital
Oxford, Oxfordshire, United Kingdom Recruiting
Study contacts
- Principal investigator: Rory J Peters — University of Oxford
- Study coordinator: Rory J Peters
- Email: Rory.peters@ndm.ox.ac.uk
- Phone: +441865220077
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
Assessing blood biomarkers and MRI for liver cancer patients undergoing radiation therapy
This study is testing if using special MRI scans and blood tests can help doctors keep track of liver health in patients with liver cancer who are getting radiation therapy.
-
Using a new imaging agent to detect various cancers
This study is testing a new imaging agent to see if it can better detect certain cancers in adults compared to standard imaging methods.
-
Liquid biopsy to differentiate types of primary liver cancer
This study is testing a new blood test to see if it can tell the difference between two types of liver cancer, hepatocellular carcinoma and intrahepatic cholangiocarcinoma, to help doctors diagnose patients more safely.
-
Navigating Care for Liver Cancer Patients
This study is trying to learn about the experiences of liver cancer patients to create a better support program that helps them and their families manage their care.
-
Evaluating liver embolization techniques for tumor management
This study tests different liver embolization methods to see how well they help people with liver tumors live longer and maintain liver function while they continue their usual treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.